Building & Validating the Predictive Power of a Patient-Derived Ex Vivo Platform to Guide Bispecific Development & Clinical Strategy
- Showcasing a patient derived ex vivo platform to test drugs and combinations directly in primary tumor material, enabling precise assessment of therapeutic index, responder likelihood and patient selection strategies before entering the clinic
- Spotlighting a PD‑1/TIGIT bispecific case study across lung and head & neck cancers, demonstrating how ex vivo response patterns aligned with clinical outcomes to validate predictive capability and inform indication prioritisation
- Discussing how AI and foundation models are trained on ex vivo datasets to build predictive classifiers that guide clinical trial design, linking molecular signatures, functional drug responses and patient specific biology to real translational decision making